|
22 Sep |
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU) |
|
20 Sep |
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference |
|
12 Sep |
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia |
|
08 Sep |
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder |
|
25 Aug |
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023 |
|
21 Aug |
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors |
|
10 Aug |
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update |
|
08 Aug |
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results |
|
07 Aug |
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders® |
|
03 Aug |
NeuBase Therapeutics to Explore Strategic Alternatives |
|
03 Aug |
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023 |
|
31 Jul |
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference |
|
17 Jul |
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease |
|
05 Jul |
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner |
|
30 Jun |
NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules |
|
29 Jun |
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing |
|
28 Jun |
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules |
|
20 Jun |
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD) |
|
14 Jun |
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs |
|
14 Jun |
NeuBase Announces 1-for-20 Reverse Stock Split |
|
12 Jun |
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders |
|
07 Jun |
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD) |
|
01 Jun |
Gain Therapeutics to Present at the Jefferies Healthcare Conference |
|
24 May |
NeuBase to Participate in Jefferies Healthcare Conference |
|
22 May |
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™ |
|
22 May |
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023 |
|
16 May |
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease |
|
16 May |
NeuBase Announces Formation of Gene Editing Advisory Board |
|
12 May |
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update |
|
11 May |
NeuBase Reports Business Update and Financial Results for the First Quarter of 2023 |
|
10 May |
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results |
|
09 May |
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET |
|
03 May |
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease |
|
02 May |
NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting |
|
13 Apr |
Leading the race to stop neurodegenerative disease progression |
|
12 Apr |
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer |
|
29 Mar |
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting |
|
29 Mar |
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results |
|
27 Mar |
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer |
|
23 Mar |
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET |
|
23 Mar |
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update |
|
22 Mar |
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders |
|
21 Mar |
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) |
|
21 Mar |
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET |
|
21 Mar |
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program |
|
09 Mar |
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET |
|
09 Mar |
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference |
|
27 Feb |
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. |
|
27 Feb |
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium |
|
14 Feb |
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023 |
|
02 Feb |
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences |
|
02 Feb |
Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023 |
|
12 Jan |
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference |
|
03 Jan |
Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering |
|
29 Dec |
Coya Therapeutics, Inc. Announces Pricing of $15.25 Million Initial Public Offering |
|
10 Nov |
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update |
|
21 Oct |
NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company |
|
14 Oct |
NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing |
|
26 Sep |
Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons |
|
22 Sep |
NeuBase to Participate at Chardan’s 6th Annual Genetic Medicines Conference |
|
20 Sep |
Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer |
|
08 Sep |
Gain Therapeutics to Present Data at Upcoming Medical Meetings |
|
06 Sep |
Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference |
|
01 Sep |
Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS) |
|
11 Aug |
NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022 |
|
08 Aug |
Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update |
|
04 Aug |
Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference |
|
02 Jun |
Gain Therapeutics to Participate at the Jefferies Healthcare Conference |
|
18 May |
Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference |
|
16 May |
Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update |
|
11 May |
Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium |
|
06 May |
Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress |
|
26 Apr |
Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference |
|
12 Apr |
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting |
|
29 Mar |
Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference |
|
24 Mar |
Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update |
|
15 Mar |
Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference |
|
13 Mar |
Neubase Therapeutics Presents New Preclinical Data At Mda 2022 For Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, And Myotonia Reversal |
|
07 Mar |
Neubase To Present At Oppenheimer’s 32nd Annual Healthcare Conference |
|
01 Mar |
Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences |
|
28 Feb |
Neubase Therapeutics To Present New Preclinical Data For Myotonic Dystrophy Type 1 Program At The 2022 Mda Clinical & Scientific Conference |
|
10 Feb |
Neubase Therapeutics Reports Business Update And Financial Results For The First Quarter Of Fiscal Year 2022 |
|
08 Feb |
Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022 |
|
04 Feb |
Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day |
|
31 Jan |
Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day (2) |
|
18 Jan |
Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences |
|
10 Jan |
Neubase Therapeutics Appoints Todd P. Branning Chief Financial Officer |
|
05 Jan |
Neubase Therapeutics Appoints Dr. Eric J. Ende To Board Of Directors |
|
23 Dec |
Neubase Therapeutics Reports Business Update And Financial Results For Fiscal Year 2021 |
Allele partners and employees publish occasional articles and present at industry conferences. To receive these materials, which describe our approach to drug and medical device development and commercialization, how we capitalize these activities and the companies that conduct them, subscribe to our news feed.